Pharmacology

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Predictive chemoinformatics applications to the pharmaceutical industry

Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the result of collective advances in chemistry, biology,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #Imaging #Lead discovery #Molecular medicine #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics

CNS Drug Discovery – Realising the dream

CNS Drug Discovery - Realising the dream By Dr Julie C. Barnes and Dr Ann G. Hayes Over the years, the discovery of drugs for treating neurological and psychiatric diseases has proven to be one of the highest risk areas in the pharmaceutical industry. Despite the huge resources that have… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biochemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Pharmacology #Preclinical #Regulatory #RNA #Stem cells #Toxicology

Obesity – The 21st century disease

Obesity - The 21st century disease By Diane L. McBay and Dr Colin T. Dourish Obesity will be the leading cause of death and disability in the 21st century. This epidemic is largely attributable to increasingly sedentary lifestyles and the abundance of tasty, high-fat foods. Obesity increases the risk of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #Preclinical #RNA #Screening #Stem cells #Target validation

Channelling Drug Discovery – Current trends in ion channel drug discovery research

Channelling Drug Discovery - Current trends in ion channel drug discovery research By Dr David Owen and Andrew Silverthorne Ion channels are proteins that span cell membranes thus forming conduits or 'channels' through which charged ions such as sodium and potassium can pass across a normally impermeant barrier such as… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #In Silico Biology #Lead discovery #Oncology #Pharmacogenomics #Pharmacology #Regulatory #RNA #System biology #Systems biology #Toxicology

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companiessq

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companies By John Wise The ability of R&D informatics to deliver real benefit to the SME pharmaceutical company is constrained by the increasing burden of non-discretionary computer systems combined with the lack of opportunity to leverage the economies of scale enjoyed… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genomics #High throughput screening #Lead discovery #Lead optimisation #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Target validation #Toxicology

From raw data in the laboratory to information availability in the enterprise

From raw data in the laboratory to information availability in the enterprise By Dieter Kreusel If pharmaceutical or biotechnology companies could measure their success merely on the volume of raw data accumulated from screening assays and pre-clinical testing, they would be basking in the glow of unprecedented success. Companies are… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology

Toxicogenomics – Insights into the present and future

By Dr Patrick J. Vojta, Vincent P. Kazmer and Dr Larry D. Kier Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on genomic responses or toxicogenomics (1). This article… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Gene therapy #Genomics #High Content Screening #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology

Metabolism Provides Alternative Door to Stroke Therapy

Metabolism Provides Alternative Door to Stroke Therapy By Dr Keith F. Martin and Tony Dolan Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs. You know that feeling you get the day after an exaggerated attempt at physical… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pathology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation

The Impact of Genomics on Regulation

The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far… Read More

#Archive

#Analysis #Animal models #Automation / robotics #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics #Toxicology

New Developments in Analgesia

New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical pain conditions and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Patent Law #Pharmacology #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Protein Therapeutics – New ladders up the fruit tree

Protein Therapeutics - New ladders up the fruit tree By Dr Richard AG Smith Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or - in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Lead discovery #Pharmacology #Pharmokinetics #Preclinical #RNA #Toxicology

e-R&D – The internet at work

e-R&D - The internet at work By Dr Alpheus Bingham and Dr Neil Bodick It is difficult to understand how the continuing growth of large monolithic Research & Development organisations can sustain the industry. With the economies of scale providing diminishing returns we examine the promise of e-R&D and explore… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Clinical specialities #Clinical trials #Drug development #Drug targets #Pharmacology #Regulatory #RNA #System biology

Modelling and simulation in drug development, promise and reality

Modelling and simulation in drug development, promise and reality By Dr Mark Sale Modelling and simulation in drug development is not new. What is new is the vision for moving from a descriptive role (what happened) to a predictive and therefore decision making role. While seemingly attractive, important hurdles, both… Read More

#Archive

#Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #QA/QC #RNA #Screening #Stem cells #Target validation #Toxicology

High Throughput Screening (HTS) – Where next?

High Throughput Screening (HTS) - Where next? By Dr Mark Beggs After approximately a decade of maturation and a three orders of magnitude increase in capabilities, High Throughput Screening (HTS) is now an established discipline within pharmaceutical discovery. But opposing stresses exist within the screening world; the resolution of which… Read More

#Archive

#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Medicinal chemistry #Pathology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Discovery Research in the Co-Genomic Era – Biology goes industrial

Discovery Research in the Co-Genomic Era - Biology goes industrial By Dr Timothy Wells and Dr Georg Feger The parallel between the search for gold in the last century and drug discovery in the co-genome era is very clear. As with all gold rushes the rewards will go to the… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Therapeutics #Toxicology

Pharmacogenomics – A new paradigm for drug development

By Michael P. Murphy, MSc Pharmacogenomics offers the opportunity to adopt a new paradigm in drug development. The pharmaceutical industry is faced with a number of challenges including relatively low productivity and success in bringing new drugs to market. Investors demand that pharmaceutical companies deliver several new drugs to the… Read More

#Archive